Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
RD-0605 in Idiopathic Inflammatory Myopathies: NCT07596680 Clinical Landscape Report 2026
16 September 2026
NCT07596680 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
RPH-035 in Multiple Sclerosis, Secondary Progressive: NCT07597668 Clinical Landscape Report 2026
16 September 2026
NCT07597668 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
KUP-101 in Mucosal Melanoma: NCT07600476 Clinical Landscape Report 2026
16 September 2026
NCT07600476 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mosunetuzumab in Lupus Nephritis: NCT07598396 Clinical Landscape Report 2026
16 September 2026
NCT07598396 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Multiple Myeloma: NCT07600151 Clinical Landscape Report 2026
16 September 2026
NCT07600151 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SYH2059 in Idiopathic Pulmonary Fibrosis: NCT07600021 Clinical Landscape Report 2026
16 September 2026
NCT07600021 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DCY636 in Dermatitis, Atopic: NCT07604324 Clinical Landscape Report 2026
16 September 2026
NCT07604324 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MT-125 in Glioblastoma, IDH-Wildtype: NCT07604285 Clinical Landscape Report 2026
16 September 2026
NCT07604285 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Asciminib Hydrochloride in Chronic phase chronic myeloid leukemia: NCT07604233 Clinical Landscape Report 2026
16 September 2026
NCT07604233 clinical landscape for Chronic phase chronic myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Anlotinib Dihydrochloride in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07602101 Clinical Landscape Report 2026
16 September 2026
NCT07602101 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Lisaftoclax in Diffuse large B-cell lymphoma refractory: NCT07601607 Clinical Landscape Report 2026
16 September 2026
NCT07601607 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Iberdomide in Extramedullary Disease in Multiple Myeloma: NCT07601100 Clinical Landscape Report 2026
16 September 2026
NCT07601100 clinical landscape for Extramedullary Disease in Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development…